Letter to the Editor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 9
Volume 18
Issue 9

In response to the article “Oncology takes blame for rising healthcare cost” (page 1, July 2009), I would like to direct Oncology News International readers to two articles on the “Win-Win” initiative. The full text articles are available online for free at:

In response to the article “Oncology takes blame for rising healthcare cost” (page 1, July 2009), I would like to direct Oncology News International readers to two articles on the “Win-Win” initiative. The full text articles are available online for free at:

“Breast Cancer Systemic Therapy: The need for more economically sustainable scientific strategies in the world,” Breast Care 3:434–438, 2008, www.karger.com/brc

“The ‘Win-Win’ initiative: A global, scientifically based approach to resource-sparing treatment for systemic breast cancer therapy,” World J Surg Oncol 7:44, 2009, www.wjso.com/content/7/1/44.

-Prof. Ahmed Elzawawy president, International Campaign for Establishment and Development of Oncology Centres, and director, South and East Mediterranean College of Oncology, Port Said, Egypt

Articles in this issue
Industry Watch
Letter to the Editor
Novel chemoRT regimen ups survival in pancreatic ca
Low expression of MSH2 protein predicts survival in NSCLC
Prostate cancer pilot program stresses patient-oriented care
Quality of life deficits offset benefits of preoperative rectal radiation therapy
CT distinguishes liver cancer mets from lung primary
Prostate cancer patients seek out mind-body care
Who's News
Panitumumab plus FOLFIRI bests FOLFIRI alone as second-line colon ca Rx
A crisis in metastatic breast ca development
Avastin shows active anti-tumor activity in brain cancer
NATCH trial finds no benefit for chemo Rx plus surgery
Lung ca staging stirs debate about noncontrast imaging
Women with metastatic breast cancer fight for a place in the ‘pink parade’
Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
1 expert is featured in this series.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Related Content
FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
August 13th 2025
Article

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

This was the first trial for patients with late-stage WM to show the potential for complete responses with a chemotherapy-free immunotherapy.

Novel CD19 CAR-NK Therapy Yields Responses in Waldenstrom Macroglobulinemia

Tim Cortese
August 13th 2025
Article

The CD19 t-haNK therapy alone and in combination with rituximab achieved complete responses and no significant toxicities in 2 patients with late-stage WM.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC

Roman Fabbricatore
August 12th 2025
Article

The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

This is the first and only therapy that improved survival when used before and after standard of care surgery in patients who are cisplatin-ineligible with MIBC.

Enfortumab Vedotin/Pembrolizumab Improved Survival Vs Surgery in MIBC

Tim Cortese
August 12th 2025
Article

Patients with cisplatin-ineligible bladder cancer who received enfortumab vedotin plus pembrolizumab and surgery had prolonged survival vs those who received surgery alone.